Diligence memo · auto-generated · as of July 2, 2026

Soricimed Biopharma Inc.

Soricimed Biopharma Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Soricimed Biopharma Inc. operates in Biotechnology, based in MONCTON.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Soricimed Biopharma Inc. has raised $2.9M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $2.8M on 2021-07-23.

Most recent recorded round closed around 2021-07-23.

Valuation (modeled)modeled

Provath models Soricimed Biopharma Inc. at approximately $69M (range $2.0M–$404M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.07× the median modeled value of Seed Biotechnology companies in 2019–2021 (186 peers) — value vs value, same stage and era. Within the normal band (107% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 59 months.

Last raise 4.9 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.0× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 33% of Biotechnology peers (4293 compared).

Modeled value ranks above 52% of those peers.

Closest niche peers: Novo Biosciences, Inc., Entac Medical, Inc., ReGelTec, Inc., Korro Bio, Inc., TamuroBio Inc..

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.